Evaluation Montelukast in the Treatment of Status Asthmaticus
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01770899|
Recruitment Status : Unknown
Verified February 2013 by Corrie Fletcher, Advocate Center for Pediatric Research.
Recruitment status was: Recruiting
First Posted : January 18, 2013
Last Update Posted : February 25, 2013
|Condition or disease||Intervention/treatment||Phase|
|Status Asthmaticus||Drug: Montelukast Drug: Placebo||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||100 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Triple (Participant, Care Provider, Investigator)|
|Official Title:||A Prospective Analysis of the Use of Oral Montelukast in Children With Status Asthmaticus|
|Study Start Date :||January 2013|
|Estimated Primary Completion Date :||December 2013|
Montelukast 5mg capsules for 2-5 year old every 24h and 8mg capsules for 6-14 year olds every 24h.
Other Name: Singulair
Placebo Comparator: Placebo
One placebo capsule given every 24h
Gelatin capsule given every 24 hours
- Improvement of pediatric asthma score [ Time Frame: Hourly during the length of the patient's pediatric ICU hospitalization for status asthmaticus ]Measurement of pediatric asthma score hourly from admission assessing for time to improvement of score, an average length of stay predicted 2-4 days.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01770899
|Contact: Corrie E Fletcher, DOfirstname.lastname@example.org|
|Contact: Luis Torero, MD||708-684‑email@example.com|
|United States, Illinois|
|Advocate Children's Hospital Oak Lawn||Recruiting|
|Oak Lawn, Illinois, United States, 60453|
|Principal Investigator: Corrie Fletcher, DO|
|Principal Investigator:||Corrie Fletcher, DO||Advocate Health Care|